Ovarian Hyperstimulation Syndrome Prevention

Not Applicable

Recruiting

• Conditions: Ovarian Hyper Stimulation Syndrome (OHSS)
• Interventions: Drug: Antagonist protocol for IVF; Drug: Modified Agonist protocol for IVF with additive treatments as HCQ

• Registration Number: NCT06739759
• Lead Sponsor: Aljazeera Hospital

Brief Summary

Ovarian hyperstimulation is a very hazardous complication of ICSI

Detailed Description

Ovarian hyperstimulation could be mild , moderate , severe or marked

Study Timeline

• Study First Submitted: 2024-10-23
• Study Start: 2024-11-17
• Status Verified: 2024-12
• Study First Submitted QC: 2024-12-13
• Last Update Submitted: 2024-12-13
• Study First Posted: 2024-12-18
• Last Update Posted: 2024-12-18
• Primary Completion: 2025-06-30
• Study Completion: 2025-07-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• Women with PCOS coming for ICSI

Exclusion Criteria

• Women who donnot have PCOS

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
antagonist	Antagonist protocol for IVF	patients with PCOS undergoing ICSI receiving antagonist protocol
Modified agonist with additives	Modified Agonist protocol for IVF with additive treatments as HCQ	Patients with PCOS undergoing ICSI receiving modified agonist protocol with additives

Primary Outcome Measures

Name	Time	Method
prevention of OHSS	within 3 weeks	prevention of symptoms of ovarian hyperstimulation syndrome as amount of ascites in litres by US

Trial Locations

Locations (2)

Algazeerah; 🇪🇬 Giza, Egypt

Aljazeerah hospital; 🇪🇬 Giza, Egypt